💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Brentuximab Vedotin

CHEMBL1742994 Phase 4 Одобрено Antibody drug conjugate
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

An antibody-drug conjugate that delivers a potent cell-killing agent (monomethyl auristatin E) directly to cancer cells expressing the CD30 protein. It is used to treat Hodgkin lymphoma and certain T-cell lymphomas. By targeting CD30, it spares many normal cells from the toxic effects of the chemotherapy payload.

Терапевтические области

Melanoma Ovarian Cancer Bladder Cancer Non-Small Cell Lung Cancer Systemic Lupus Erythematosus Lymphoma Breast Cancer Leukemia

Механизм действия

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

An antibody-drug conjugate that delivers a potent cell-killing agent (monomethyl auristatin E) directly to cancer cells expressing the CD30 protein. It is used to treat Hodgkin lymphoma and certain T-cell lymphomas. By targeting CD30, it spares many normal cells from the toxic effects of the chemotherapy payload.

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Yes, Brentuximab Vedotin is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1742994. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.